Scarica l'app Stockscreener
3.16
5.11%
-0.17
Dopo l'orario di chiusura:
3.24
0.08
+2.53%
Precedente Chiudi:
$3.33
Aprire:
$3.35
Volume 24 ore:
802.54K
Relative Volume:
0.97
Capitalizzazione di mercato:
$436.97M
Reddito:
-
Utile/perdita netta:
$-45.44M
Rapporto P/E:
-9.0286
EPS:
-0.35
Flusso di cassa netto:
$-42.28M
1 W Prestazione:
+0.32%
1M Prestazione:
+20.61%
6M Prestazione:
+19.25%
1 anno Prestazione:
+230.92%
Intervallo 1D:
$3.13
$3.365
Intervallo di 1 settimana:
$2.96
$3.45
Portata 52W:
$0.8741
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Nome
Compass Therapeutics Inc
Settore
Industria
Telefono
617-500-8099
Indirizzo
80 GUEST STREET, BOSTON
Confronta CMPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.16 | 424.53M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2025-04-02 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Iniziato | Guggenheim | Buy |
| 2025-02-19 | Iniziato | Piper Sandler | Overweight |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Iniziato | Jefferies | Buy |
| 2023-01-27 | Iniziato | Stifel | Buy |
| 2022-05-23 | Ripresa | H.C. Wainwright | Buy |
| 2022-03-15 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-01-19 | Iniziato | B. Riley Securities | Buy |
| 2021-12-22 | Iniziato | Raymond James | Outperform |
| 2021-12-20 | Iniziato | SVB Leerink | Outperform |
| 2021-12-15 | Iniziato | Wedbush | Outperform |
Mostra tutto
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
What analysts say about Compass Therapeutics Inc. stockExtraordinary market timing - Autocar Professional
Compass Therapeutics (CMPX) Soars 8.47% on Analyst Endorsement - AInvest
Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline - MSN
What drives Compass Therapeutics Inc. stock priceFree Stock Market Trend Analysis - jammulinksnews.com
Compass Therapeutics Inc. Stock Analysis and ForecastAccelerated capital growth - jammulinksnews.com
Is Compass Therapeutics Inc. a good long term investmentRemarkable growth - jammulinksnews.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
Is Compass Therapeutics Inc. stock a growth or value playHigh Return Setup Scanner - beatles.ru
What analysts say about Compass Therapeutics Inc. stock outlookFree Real-Time Market Predictions - beatles.ru
What makes Compass Therapeutics Inc. stock price move sharply10x Return With Managed Risk - Newser
Why Compass Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
How Axsome Therapeutics Inc. stock performs during market volatilityMulti Bagger Alerts - Newser
How Compass Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Stifel reiterates Buy rating on Compass Therapeutics stock with $11 target - Investing.com Canada
Contrasting Compass Therapeutics (NASDAQ:CMPX) & Generation Bio (NASDAQ:GBIO) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Buy” by Brokerages - Defense World
Compass Therapeutics (CMPX) soars 4.01% on FDA Fast Track Designation - AInvest
Vontobel Holding Ltd. Invests $57,000 in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
H.C. Wainwright Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Raises Target Price to $24 - 富途牛牛
Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Earn Buy Rating - AInvest
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Raymond James Financial - Defense World
H.C. Wainwright Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics, Inc.(NasdaqCM: CMPX) added to Russell 3000E Growth Index - MarketScreener
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer - TipRanks
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Benzinga
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Bank of America Corp DE - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Sells 48,021 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Confirms Directors at Annual Meeting - TipRanks
Cholangiocarcinoma Market Booming Worldwide, Estimated to Reach USD 2,334.4 Mn by 2032 | Incyte CorporationSOUTHEAST - SOUTHEAST - NEWS CHANNEL NEBRASKA
Compass Therapeutics Inc Azioni (CMPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):